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ABSTRACT
Background
The prognostic value of the ectopic activation of TLX3 gene expression, a major oncogenetic
event associated with pediatric T-cell acute lymphoblastic leukemia, is controversial. Likewise,
the frequency and the prognostic significance in pediatric T-cell acute lymphoblastic leukemia
of the newly characterized NUP214-ABL1 fusion transcript is not yet clear.
Design and Methods
Two hundred children with T-cell acute lymphoblastic leukemia were treated in the French
FRALLE-93 study from 1993 to 1999.The expression of TLX3, TLX1 and SILTAL1 genes was ana-
lyzed in samples from 92 patients by real-time quantitative reverse transcriptase polymerase
chain reaction. Most of these samples were further studied for NUP214-ABL1 and CALM-AF10
fusion transcripts.
Results
The median follow-up was 7.9 years. At 5 years the overall survival (± standard deviation, %)
was 62 (±3%) and leukemia-free survival was 58 (±3%). Patients with T-cell acute lymphoblas-
tic leukemia positive for TLX3 had a poorer survival compared to those with T-ALL negative for
TLX3 (overall survival: 45±11% vs. 57±5%, p=0.049). In multivariate analysis, TLX3 expression
was an independent adverse risk factor predicting relapse with a hazard ratio of 2.44
(p=0.017) and an overall survival with a hazard ratio of 3.7 (p=0.001). NUP214-ABL1 was
expressed in 16.6% of patients with TLX3-positive T-ALL (3 of 18); all of the patients with this
association died before completion of the treatment. SILTAL expression did not significantly
affect the prognosis of patients with T-cell acute lymphoblastic leukemia. Only three of 92
patients expressed the TLX1 gene and all three are alive.
Conclusions
TLX3 gene expression is an independent risk factor predicting poor survival in childhood T-cell
acute lymphoblastic leukemia. When co-expressed with TLX3, NUP214-ABL1 transcripts may
increase the risk of poor survival.
Key words: childhood T-cell acute lymphoblastic leukemia, TLX3/HOX11L2, NUP214-ABL1,
SIL-TAL1, outcome.
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Introduction
T-cell acute lymphoblastic leukemia (T-ALL)
accounts for 10 to 15% of cases of childhood acute
lymphocytic leukemia and is often associated with
unfavorable features. The prognosis of this disease,
although improved over the last years because of the
use of more intensive treatments and risk-adapted
therapy, remains unsatisfactory.1-5 Thus, the identifi-
cation of prognostically relevant molecular markers at
diagnosis will be fundamental to guide risk-adapted
strategies and contribute to the optimization of T-ALL
treatment.
T-ALL are characterized by recurrent translocations
affecting the T-cell receptor loci (TCR). Consequently,
enhancer elements from the TCRA/D locus (14q11)
and TCRB locus (7q34) come close to target genes and
activate their ectopic expression. This mechanism
implies a number of transcription factors such as the
helix-loop-helix genes (TAL1/SCL, TAL2, LYL1),6-10 the
LIM-domain-only (LMO1, LMO2) genes, the home-
obox genes of class-I (HOXA10, HOXA11)11,12 or class-
II (HOX11/TLX1, HOX11L2/TLX3)13,14 and the
NOTCH1 gene.15 The same genes are frequently tar-
geted during the malignant transformation of T cells
by others mechanisms, such as interstitial deletion on
chromosome 1 for TAL1/SCL or point mutations for
NOTCH1.16,17
Other translocations, not involving TCR loci, have
also been described: the t(10;11)(p13;q14) transloca-
tion,18,19 resulting in the CALM-AF10 fusion gene; the
cryptic t(5;14) (q34;q32) translocation,14 resulting  in
the ectopic transcription of TLX3/HOX11L2 and the
episomal 9q34 recombination between NUP214 and
ABL1 genes.20 These two latter events are highly spe-
cific to T-ALL, occurring in, respectively, 20-24% and
5-6% of cases. For an unexplained reason, NUP214-
ABL1 fusion appears closely associated with TLX1 and
TLX3 deregulation. Until recently there have been no
reports of this episomal recombination in others types
of leukemia and very little is known about its frequen-
cy in pediatric T-ALL. Furthemore, it is still unclear
how these genetic lesions affect the prognosis of
patients with T-ALL. Few cohorts of patients have
been analyzed so far and for more recently character-
ized lesions such as the NUP214-ABL1 fusion gene, no
studies in childhood T-ALL are available. Preliminary
analyses of the prognostic value of frequent lesions
such as ectopic TLX3 activation have led to contrast-
ing conclusions.21-14
Here, we analyzed the prognostic value of TLX3
expression on the clinical outcome of 92 patients with
T-ALL enrolled in the FRALLE-93 study between
1993-1999. Moreover, to gain insights into the rela-
tionship between TLX3 and other oncogenetic events
we extended our analysis to SILTAL and TLX1 gene
expression, as well as to molecular lesions such as
NUP214-ABL1 and CALM-AF10 gene fusions which
have not yet been extensively evaluated in pediatric T-
ALL.
Design and Methods
Patients and the FRALLE-93 trial design
Between 01.1993 and 31.12.1999, 1395 children (778
boys and 617 girls) with ALL were included in the
FRALLE-93 protocol. The leukemia was classified as B-
cell lineage in 1195 cases (86%) and T-cell lineage in 200
cases (14%). All the patients with T-ALL were included
in this study and uniformly assigned to the high-risk
group. Informed consent was obtained from the
patients’ parents in all cases. The treatment design is
summarized in Online Supplementary Figure S1. High-risk
patients were assigned to three different treatment sub-
groups according to their response to prednisone at day
8 and the blast count in bone marrow evaluated at day
21. Prednisone response was defined as good when the
number of blasts circulating in the blood was < 1000/µL
at day 8 or poor when the circulating blast count was
>1000/µL at day 8. The persistence of blasts in the bone
marrow at day 21 was categorized as M1 when the
blast count was <5%, M2 when the count was between
5% and 25% and M3 when it was >25%. Group C1,
patients, who had a good response to prednisone and
M1 or M2 bone marrow involvement, received two
delayed intensification blocks; group C2, patients con-
sidered at a very high risk because of poor response to
prednisone and/or M3 bone marrow involvement,
received six intensification blocks, followed by autolo-
gous stem cell transplantation or, group C3, by allogene-
ic stem cell transplantation if an HLA-matched sibling
was available. Central nervous system prophylaxis con-
sisted in triple intrathecal injection with methylpred-
nisolone, methotrexate, cytarabine and 18 Gy radio-
therapy. The details of the treatment for group C2 have
been published elsewhere25 The main characteristics of
the patients studied are presented in Table 1. T-cell lin-
eage was assessed on the basis of expression of CD3,
CD2, CD5 and CD7 antigens and exclusion of B-cell-
associated antigens according to the European EGIL rec-
ommendations.26 Karyotypes and fluorescence in situ
hybridization (FISH) analysis of t(5;14) translocation of
cases analyzed for TLX3 expression have already been
reported.27 Molecular studies for SILTAL, TLX3 and TLX1
were possible in 92 out 200 samples (46%). This was
mainly related to the fact that systematic cryopreserva-
tion of T-ALL blasts was not performed in all the partic-
ipating centers. Additional analysis of CALM-AF10 and
NUP214-ABL1 was carried out in 84 and 52 patients,
respectively. 
Molecular studies
RNA was extracted and reverse transcribed according
to previously described procedures.21 Expression of SIL-
TAL, TLX3 and TLX1 was analyzed by real time quanti-
tative polymerase chain reaction (RQ-PCR) on a
Taqman 7700 or 7500 real time PCR device (Applied
Biosystems, Les Ulis, France) and their levels of expres-
sion were quantified relative to the expression of the
endogenous control gene, ABL. Primers and probes for
ABL1 and SILTAL as well as the RQ-PCR procedures are
described in the Europe-Against-Cancer Program.28,29
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TLX1 and TLX3 gene expression was detected as report-
ed elsewhere.21 CALM-AF10 fusion transcripts, both 5’
and 3’ fusions, and the more frequent NUP214-ABL1
fusion transcripts were screened for as reported previ-
ously.20, 30
Statistical analysis 
Two different descriptive analyses were performed,
the first on the overall population of patients, the sec-
ond on the sub-population of patients for whom molec-
ular data were available. Variables considered were
patients’, age and  gender, and disease and treatment
characteristics. Leukemia-free survival was defined as
survival without evidence of relapse or progression.  All
patients still alive in first continuous remission were
censored at their last follow-up. Probabilities of overall
survival and leukemia free survival were calculated
using the Kaplan-Meier estimate. Further analyses were
performed only on patients with available molecular
data to evaluate the clinical significance of the oncoge-
netic events. Patient-, disease-, and treatment-related
variables of the groups divided according to oncogenet-
ic events were compared using the χ2 statistic for cate-
gorical variables and the Mann-Whitney test for contin-
uous variables. The log-rank test and Cox proportional
hazards model were used to determine the univariate
and independent prognostic importance of several vari-
ables. All variables with a p value less than 0.2 in the
univariate analysis or differing in distribution were
entered into the model. The type I error rate was fixed
at 0.05 for the determination of factors associated with
time to event outcomes.  Statistical analyses were per-
formed with SPSS (Inc., Chicago, USA) software pack-
ages.
Results
Patients and FRALLE-93 trial design
The biological and clinical characteristics of the entire
cohort of FRALLE-93 T-ALL patients are summarized in
Table 1. One hundred and sixty-eight patients out of
200 reached complete remission. The follow-up period
ranged from 4.3 to 11.8 years (median, 7.9 years). The
overall and leukemia-free survival rates of the FRALLE-
93 T-ALL population were 62% (±3%) and 58% (±3%),
respectively, at 5 years and 60% (±4%) and 56% (±4%)
at 10 years. As shown in Table 1 the subgroup of 92
patients who underwent genetic analysis is representa-
tive of the total population, as there were no differences
in clinical presentation, initial response to chemothera-
py, or subsequent treatments between the subgroup and
the total population.
Frequency and distribution of the genetic lesions
among the study population
High and specific over-expression of TLX3 and TLX1
was found in 21.7% (20/92) and 3.2% (3/92) of the
cases, respectively. SILTAL and CALM-AF10 5’- or 3’-
fusion transcripts were detected in an additional 21.7%
(20/92) and 4.7% (4/84) of samples tested. NUP214-
ABL1 fusion transcripts were found in three (5.8%) of
52 T-ALL samples: two had a fusion between NUP214
exon 29 and ABL1 exon 2 and one between NUP214
exon 30 and ABL1 exon 2. All the three cases of T-ALL
positive for a NUP214-ABL1 fusion were also positive
for TLX3 activation. 
Clinical and biological characteristics at diagnosis
according to the oncogenetic lesions
Five distinct molecular subgroups could be identified
within the study population SILTAL, HOX11L2/TLX3,
HOX11/TLX1, CALM-AF10 and NUP214-ABL1. Except
for the NUP214-ABL1 gene fusion, none of the other
lesions studied was found to be co-expressed in the
same leukemic sample. As shown in Table 2 there were
no differences between these molecular subgroups in
sex ratio, age or mediastinal involvement, although ini-
tial leukocytosis did differ. The white blood cell count
was significantly higher in the SILTAL subgroup than in
the TLX3, TLX1 and NUP214-ABL1 subgroups. Marked
hyperleukocytosis and mediastinal involvement were
also noted in the group of patients with CALM-AF10 T-
ALL. Conventional cytogenetic analysis was conducted
in 169 patients and was normal in half of these cases
P. Ballerini et al. 
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Table 1. Clinical characteristic of the overall pediatric T-ALL cohort
and of the study population.
FRALLE-93 T-ALL cohort Study population
Total n=200 n=92
Median age, years, at diagnosis 9.15 (1.1-19.5) 9.7 (1.7-18.5)
(range)
Median year of diagnosis 1996 (93-99) 1997 (93-99)
Patients’ gender: male/female 139/61 63/29 
69% - 31% 68% - 32% 
Median WBC at diagnosis, 98,85 (0,6-1247) 149.5 (0.6-736)
×109/L (range)
WBC >50 ×109/L 126 (63%) 68 (74%)
Mediastinal involvement 141 (70%) 66 (71%)
Response to pre- phase treatment
PPR 109 (57%) 45 (52%)
GPR 82 (43%) 41 (39%)
M status
M1 135 (69%) 68 (73%)
M2 21 (11%) 11 (12%)
M3 40 (20%) 11 (12%)
NE 4 2
Risk group of the protocol
C1 100 (59%) 46 (55%)
C2 44 (26%) 23 (28%)
C3 24 (14%) 14 (17%)
Stem cell transplant (SCT)
allogeneic 32 (16%) 16 (17%)
autologous 39 (20%) 18 (20%)
no SCT 129 (65%) 58 (63%)
Follow-up, years (range) 7.9 (4.3-11.8) 7.4 (4.2-11.8)
5-year leukemia-free survival 58±3% 64±5%
5-year overall survival 62 ± 3% 56 ± 5%
WBC, white blood cell count; GPR: good prednisone response; PPR: poor pred-
nisone response; M1-2-3 status: percentage of blasts in the bone marrow at day
21.
(87/169). Within the TLX3 subgroup, only four cases
displayed abnormal karyotypes involving chromosome
5 (addition of 5q, monosomy 5, and deletion of 5q).
FISH analysis confirmed the presence of translocation of
the TLX3 locus on 5q35 in all the cases analyzed (8/16).
In the SILTAL subgroup, six cases displayed karyotype
abnormalities, mostly involving chromosome 6 (dele-
tion of 6p, n=1, or 6q, n=3). No 10q24 chromosome
rearrangement was detected in the TLX1 subgroup. In
the CALM-AF10 subgroup, the karyotypes were normal
in three of four cases. Episomal distribution of NUP214-
ABL1 was confirmed by FISH analysis in the only case
studied in this subgroup. Overall, the frequency of cyto-
genetic alterations was similar in the different oncoge-
netic subgroups.
Analysis of the prognostic impact of oncogenetic
events
TLX3 and SILTAL. The clinical response to treatment
and the survival of patients in each oncogenetic sub-
group are detailed in Table 3. Kaplan-Meier estimates of
overall survival for patients with TLX3 and SILTAL
lesions are represented in Figure 1. T-ALL positive for
TLX3 gene expression did not differ significantly from
TLX3-negative ones with respect to prednisone-poor
response (p=0.11), bone marrow blast count (M status) at
day 21 (p=0.81), complete remission rate (p=0.54) and
treatment subgroups: C1 vs. C2 vs. C3 (p=0.44). Patients
with SILTAL-positive T-ALL had hyperleukocytosis and
many had a poor response to prednisone at day 8 (58%),
but they had an excellent response to induction
chemotherapy (95% M1 for SILTAL-positive patients vs.
TLX3/HOX11L2 expression predicts adverse outcome in childhood T-ALL
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Table 2. Clinical and biological characteristics at diagnosis of the patients divided according to the presence of oncogenetic lesions. 
FRALLE-93   T-ALL cohort SILTAL positive TLX3 positive TLX1 positive NUP214-ABL1 positive CALM-AF10 positive
Total number, n 200 20/92 20/92 3/92 3/52 4/84
(%) 21.7% 21.7% 3.2% 5.8% 4.7%
Gender, male/female 139/61 13/7 13/7 2 / 1 3/0 3 /1
Age, median, years 9.15 6.5 9.25 9.8 11.6 9.8
(range) (1.1-19.5) (2.3-17.8) (3.2-18.5) (4.8-11.8) (5-13.5) (4.3-16.4)
WBC, median 98.85 238.5 116.7 140 66 426
(range, ×109/L) (0.6-1247) (3.5-636) (1.9 - 736) (5.4-256) (12.4-736) (260-606)
<50 ×109/L (n) 75 1 7 1 1 0
50-99 ×109/L (n) 25 2 3 0 1 0
≥100 ×109/L (n) 100 17 10 2 2 4
Mediastinal involvement, (n) 141 13 14 0 1    4
Karyotype 
Abnormal, n 82 6 4 1 0 0
Normal, n 87 11 12 1 2 4
Not evaluable, n 31 3 4 1 1 0
Table 3. Clinical response to treatment, distribution and type of events, and survival status in subgroups divided according to the pres-
ence of oncogenetic lesions.
FRALLE-93 T-ALL all TLX3 neg. TLX3 pos SILTAL pos TLX1 pos NUP214-ABL1 pos CALM-AF10 pos
Total number, (n) (200) (72) (20) (20) (3) (3) (4)
Response to prephase, n
died before evaluation 4 2 0 0 0 0 0
GPR <1000 blasts/µL 109 32 13 8 3 0 4
PPR >1000 blasts/µL 82 35 6 11 0 3 0
not evaluated 5 3 1 1 0 0 0
M status at day 21, n
died before evaluation 4 2 0 0 0 0 0
M1 135 54 14 19 2 1 3
M2 21 8 3 1 1 0 1
M3 40 8 3 0 0 2 0
Type of event, n
No eventa 110 42 9 12 3 0 3
Failure 20 5 1 0 0 0 0
early deaths 4 1 0 0 0 0 0
relapses 66b 24 10a 8d 0 3 1
toxic deaths 3 0 0 0 0 0 0
Leukemia-free survival % ± SE 58±3 60±5 45±11 70±10 not evaluable not evaluable not evaluable
Overall survival % ± SE 62±3 57±5 45±11 80±9 not evaluable not evaluable not evaluable
Alive, n 122 64 9 15 3 0 1
aContinuous complete remission; bRelapses occurred in bone marrow (BM) (n=42), central nervous system (CNS) (n=6), BM+CNS (n=5), testis (n=3) and medi-
astinum (n= 10); CRelapses occurred in BM(n= 9) and testis (n=1) ; dRelapses occurred in BM (n=3), CNS (n=3), BM+CNS (n=1) and mediastinum (n=1).  
65% MI for SILTAL-negative patients, p=0.008) (Table 3).
In univariate analysis only two factors were significant-
ly correlated with a lower 5-year overall survival rate: a
poor response to prednisone (p=0.001) and TLX3 status
(p=0.049) (Table 4). A shorter leukemia-free survival was
significantly correlated only to a poor response to pred-
nisone (p=0.002). It is noteworthy that M3 status did not
significantly predict patients’ outcome (leukemia-free
survival p=0.11; overall survival p=0.09). Patients with
SILTAL-positive T-ALL appeared to have a better long-
term outcome than those without this genetic lesion,
although the difference was not statistically significant
(p=0.1) (Figure 1). In a multivariable analysis, a poor
response to prednisone at day 8 and over-expression of
the TLX3 gene independently predicted adverse out-
come. The hazard ratios for 5-year leukemia-free sur-
vival and overall survival for patients with a poor
response to prednisone were 3.6 (p=0.01) and 4.8
(p<0.0001), respectively. The corresponding hazard
ratios for patients with TLX3-positive T-ALL were 2.44
(p 0.017) and 3.7 (p=0.001), respectively (Table 5).
Outcome of T-ALL in other oncogenetic groups 
A detailed description of the other subgroups is given
in Table 3. The low number of positive samples in each
P. Ballerini et al. 
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Figure 1. Kaplan Meier analysis of (A) leukemia-free survival
according to TLX3 expression and (B) overall survival according to
TLX3 expression and (C) overall survival according to SILTAL
expression.
Table 4. Univariate analysis of factors associated with 5-year over-
all survival (OS) and leukemia-free survival (LFS) in the study pop-
ulation.
OS p LFS p
Age 
Below median 67±7% 63±7%
Median or above 61±7% 54±7%
0.47 0.4
Year of diagnosis
Before median 61±7% 54±7%
Median or after 67±7% 63±7%
0.56 0.44
White blood cell count
< median (149.5 ×109/L) 65±7% 59±7%
≥ median 63±7% 59±7%
0.93 0.89
Response to steroids at day 8
Good 80±6% 73±6%
Poor 46±8% 41±8%
0.001 0.002
M status
M1+ M2 68±5% 63±5%
M3 45±15% 36±14%
0.09 0.11
TLX3
negative 69±5% 63±6%
positive 45±11% 45±11%
0.049 0.2
SILTAL
negative 59±6% 55±6%
positive 80±9% 70±10%
0.1 0.26
M1-2-3 status: percentage of blasts in the bone marrow at day 21.
Table 5. Multivariate analysis of factors associated with  leukemia-
free survival and overall survival at 5 years in the FRALLE-93 T-ALL
study population.
Leukemia-free survivala Hazard ratio 95% confidence interval p value
Poor response to prednisone 3.57 7.14-1.72 0.001
TLX3 positive vs. negative 2.43 5.26-1.17 0.017
Overall survivala,b
Poor response to prednisone 4.76 11.11-2.08 <0.0001
TLX3 positive vs. negative 3.7 8.33-1.69 0.001
aCox regression model with all covariates associated with a p value less than 0.2
by univariate analysis: bsame as for leukemia-free survival but without SILTAL
status which had a p value of  0.26.
Leukemia-free survival according to TLX3 expression in the study population (92 patients)
Overall survival according to TLX3 expression in the study population (92 patients)
Overall survival according to SIL-TAL expression in the study population (92 patients)
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group precluded a reliable statistical evaluation of their
clinical impact, nevertheless all three patients with
TLX1 expression had an excellent outcome whereas all
three patients with the association of NUP214-ABL1
and TLX3 expression died before completion of their
treatment.
Discussion
In the present study, we analyzed the prognostic
value of five different genetic abnormalities, SILTAL,
TLX3, TLX1, CALM-AF10 and NUP214-ABL1 in a large
panel of cases of pediatric T-ALL treated in the FRALLE-
93 trial. We were able to classify at the molecular level
up to 50% (47/92) of the T-ALL cases studied and
demonstrate that TLX3 overexpression is an independ-
ent risk factor in pediatric T-ALL, predicting an inferior
outcome. That risk may increase when the NUP214-
ABL1 fusion is co-expressed.
Very little is known about the role of the TLX3 gene
in leukemic hematopoiesis. Recently, unsupervised hier-
archical analysis of T-ALL gene expression profiles
demonstrated a major cluster sharing a common gene
expression signature, which included TLX1, TLX3-
expressing cases and HOXA-translocated cases.12
Nervertheless, the contributions of TLX3 and TLX1 to
the leukemic process could be quite different since actu-
al data on clinical outcome seem to be opposing for
these two lesions in adult T-ALL22,31,32 as well in pediatric
T-ALL.24 Moreover, the high frequency of ectopic  TLX3
activation in pediatric T-ALL suggests that this gene
plays a crucial role. Conflicting results have been report-
ed21-24 on the prognostic value of TLX3 activation in
pediatric T-ALL. Confounding elements, such as hetero-
geneity of patient cohorts and clinical trials and differ-
ences in therapeutic strategies, might explain such dis-
crepancies.
The survival of patients with T-ALL has improved
over the past 10 years, especially in paediatric co-opera-
tive studies, because of more intensive post-induction
chemotherapy.2,3 Nevertheless, a subgroup usually iden-
tified as being at very high risk, generally including
prednisone-poor responders and/or slow responders to
early chemotherapy (M3), still have a high mortality
rate. Our analysis confirmed the pejorative impact of a
poor response to prednisone on both leukemia-free and
overall survival in the FRALLE-93 T-ALL cohort and
showed that TLX3 activation is of significant value in
predicting worse outcome in terms of overall and
leukemia-free survival independently of the prednisone
response at day 8. Interestingly, we observed that TLX3
expression was more significantly associated with infe-
rior survival than was M3 status (TLX3 positivity,
p≥0.049 vs. M3 status, p=0.09). Our data confirm the
findings of Ferrando22 in a cohort of 59 children and
young adults treated at St. Jude hospital,33 and the more
recent results of van Grotel et al. in two independent
cohorts of 72 and 53 children treated according to the
DCOG ALL7/8 and COALL-97 protocols, respectively.24
In the latter study, with a median follow up of 3 years,
TLX3 expression was significantly predictive of a poor
outcome in both univariate (log-rank p=0.014) and mul-
tivariate analysis (log-rank p=0.039). As in our study, the
patients had a high median white blood cell count
(135×109/L) and similarly, the most marked hyperleuko-
cytosis was observed in the SILTAL and CALM-AF10
subgroups. 
Our data reinforce results from adult T-ALL stud-
ies.31,34 An analysis of potential risk factors among the 92
T-ALL patients treated in the LALA94 trial31 clearly indi-
cated an association between TLX3 expression and infe-
rior overall survival (13% vs. 47%; p=0.009). Similar
data emerged from the analysis of 100 patients with T-
ALL treated in the GMALL 05/93 and 06/99 trials
between 1993 and 2000, reported by Baldus et al.34
Our results do, however, differ from those reported
by Cavé et al.23 These authors did not observe any pejo-
rative effect associated with TLX3 expression in a
cohort of 138 T-ALL cases treated with EORTC 58881
(n=75) and 58951(n=78) protocols between 1989 and
2002. As in the case of the FRALLE-93 protocol, the gen-
eral design of the 58881 trial had many similarities with
that of the ALL-BFM90 trial and treatment results of T-
ALL patients included in the very high risk and standard
risk groups were also similar, with global leukemia-free
survival rates of 61.7%±3.6 and 63.8%±6.7, respective-
ly, at 8 years. The overall survival of T-ALL patients
reported by Cavé et al. was 78%, thus higher than in the
58881 study. This difference could result from a bias in
sample recruitment over the period, reflecting the better
outcome of patients treated in the more recent 58951
study. In any case, the low number of events in that
cohort of patients does not allow the detection of signif-
icant differences among subgroups. 
Some features of the patient population at diagnosis
in the Cavé’s study differed strikingly from our and
from other studies. Firstly, the median white blood cell
count in the EORTC cohort was lower than in the
FRALLE cohort (49×109/L vs. 98.85×109/L); this was also
the case for the subgroups expressing TLX3 (34×109/L
vs. 120×109/L), SILTAL (124×109/L vs. 238.5×109/L) and
TLX1 (29×109/L vs. 140×109/L). Secondly, the median
age of patients positive for TLX3, and TLX1 was lower
than in the FRALLE cohort (6 and 5 vs. 9.2 and 9.8 years,
respectively) whereas the median age of SILTAL- posi-
tive patients was higher (11 vs. 6 years). These differ-
ences are difficult to explain but they could be revelant
to the interpretation of the results. 
Besides the differences in patient populations and
treatment efficacy, another explanation of the difference
in the prognostic relevance of TLX3 may be the pres-
ence of associated oncogenetic events. The recent find-
ing of NUP214-ABL1 episomal fusions within T-ALL
patients positive for TLX3 or TLX1 activation could sup-
port this hypothesis. We observed a global frequency of
NUP214-ABL1 of 5.8%, which is in agreement with a
previous report,20 with the frequency increasing to 16%
(3 of 18) among the TLX3-positive subgroup. Our data
show that this association may effectively worsen clin-
ical outcome, as suggested by Graux et al., and a search
for NUP214-ABL1 should be systematically included in
the investigation of TLX3-positive cases of T-ALL.
In keeping with the studies mentioned above, patients
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with SILTAL-positive T-ALL showed very high white
blood cell counts at diagnosis and were more frequently
poor responders to prednisone at day 8 of treatment.
Nevertheless, SILTAL expression did not affect signifi-
cantly either leukemia-free survival or overall survival.
One possible explanation is that TAL1 expression and/or
reactivation is a frequent oncogenetic event associated
with T-ALL, even in the absence of structural alterations
of its locus.12,21 The levels of TAL1 expression are highly
variable and not directly linked to the underlying mech-
anism of activation. Thus, it would be interesting, as in
the case of TLX1 expression,35 to identify what level of
expression has a direct impact on the prognosis.
We observed a favorable outcome in patients with
TLX1-positive T-ALL, which appears consistent with
observations in adults suggesting a positive association
between TLX1 expression and good responder patient.32
Finally, we were unable to confirm previous data sug-
gesting a pejorative role of CALM-AF10 fusion tran-
scripts.30,36 but with only four positive cases and one
event in this subgroup, statistical analysis of the clinical
impact of this lesion would not be reliable. 
In conclusion, our study highlights the importance of
TLX3 activation as a new and powerful risk predictor in
pediatric patients with T-ALL. TLX3 expression and the
presence of NUP214-ABL1 should be taken into account
when evaluating patients with high-risk disease in order
to improve outcome in pediatric T-ALL.
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